Dexcom Inc (NASDAQ: DXCM) has a higher price-to-earnings ratio of 47.54x compared to its average ratio. DXCM has 36-month beta value of 1.12. Analysts have mixed views on the stock, with 15 analysts rating it as a “buy,” 5 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for DXCM is 385.55M, and currently, short sellers hold a 2.36% ratio of that float. The average trading volume of DXCM on December 03, 2024 was 4.31M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DXCM) stock’s latest price update
Dexcom Inc (NASDAQ: DXCM)’s stock price has plunge by 1.69relation to previous closing price of 77.99. Nevertheless, the company has seen a 8.90% surge in its stock price over the last five trading sessions. fool.com reported 2024-12-02 that Medical device specialist DexCom (DXCM -0.14%) is going through a rough patch. The company’s shares are down sharply year to date due to unimpressive financial results — and some of the headwinds it has encountered are, no doubt, concerning.
DXCM’s Market Performance
Dexcom Inc (DXCM) has experienced a 8.90% rise in stock performance for the past week, with a 12.53% rise in the past month, and a 9.60% rise in the past quarter. The volatility ratio for the week is 3.43%, and the volatility levels for the past 30 days are at 3.45% for DXCM. The simple moving average for the last 20 days is 7.26% for DXCM stock, with a simple moving average of -21.02% for the last 200 days.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with Robert W. Baird repeating the rating for DXCM by listing it as a “Neutral.” The predicted price for DXCM in the upcoming period, according to Robert W. Baird is $80 based on the research report published on July 26, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $75, previously predicting the price at $145. The rating they have provided for DXCM stocks is “Neutral” according to the report published on July 26th, 2024.
Redburn Atlantic gave a rating of “Neutral” to DXCM, setting the target price at $130 in the report published on May 30th of the current year.
DXCM Trading at 11.06% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.15% of loss for the given period.
Volatility was left at 3.45%, however, over the last 30 days, the volatility rate increased by 3.43%, as shares surge +12.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.61% upper at present.
During the last 5 trading sessions, DXCM rose by +8.90%, which changed the moving average for the period of 200-days by -32.61% in comparison to the 20-day moving average, which settled at $73.94. In addition, Dexcom Inc saw -36.09% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Stern Sadie, who sale 4,259 shares at the price of $74.73 back on Nov 20 ’24. After this action, Stern Sadie now owns 71,192 shares of Dexcom Inc, valued at $318,275 using the latest closing price.
Sylvain Jereme M, the EVP, Chief Financal Officer of Dexcom Inc, sale 3,500 shares at $75.51 during a trade that took place back on Nov 15 ’24, which means that Sylvain Jereme M is holding 80,774 shares at $264,285 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.62 for the gross margin
The net margin for Dexcom Inc stands at 0.17. The total capital return value is set at 0.14. Equity return is now at value 32.06, with 10.51 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.33. The debt to equity ratio resting at 1.24. The interest coverage ratio of the stock is 33.05.
Currently, EBITDA for the company is 916.7 million with net debt to EBITDA at 2.02. When we switch over and look at the enterprise to sales, we see a ratio of 8.33. The receivables turnover for the company is 3.83for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.46.
Conclusion
To put it simply, Dexcom Inc (DXCM) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
